Cardiology Today -- Patients receiving intensive lipid-lowering therapy with atorvastatin following acute coronary syndromes had reduced primary and subsequent adverse events, results of an analysis of the PROVE IT-TIMI 22 trial suggested.
Cardiology Today -- Patients receiving intensive lipid-lowering therapy with atorvastatin following acute coronary syndromes had reduced primary and subsequent adverse events, results of an analysis of the PROVE IT-TIMI 22 trial suggested.